{"id":"cuvitru-20-injectable-solution","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Nausea"},{"rate":"<1","effect":"Thrombotic events"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cuvitru is a subcutaneous immunoglobulin (SCIg) replacement therapy derived from pooled human plasma. It works by restoring deficient or dysfunctional antibodies in patients with primary immunodeficiency disorders, enabling them to mount appropriate immune responses against infections. The therapy provides immediate passive immunity and helps prevent recurrent bacterial and viral infections.","oneSentence":"Cuvitru is a human immunoglobulin (antibody) replacement therapy that provides passive immunity by supplying functional antibodies to patients with primary immunodeficiency.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:29.782Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders requiring immunoglobulin replacement"},{"name":"Secondary immunodeficiency in patients unable to produce adequate antibodies"}]},"trialDetails":[{"nctId":"NCT02915263","phase":"PHASE2","title":"The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-09-11","conditions":"Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies","enrollment":13},{"nctId":"NCT03401073","phase":"PHASE2","title":"IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-09-01","conditions":"Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy","enrollment":20},{"nctId":"NCT03116347","phase":"PHASE4","title":"Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-05-30","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":42},{"nctId":"NCT03737617","phase":"PHASE4","title":"Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis","status":"WITHDRAWN","sponsor":"University of Edinburgh","startDate":"2022-08-05","conditions":"Bronchiectasis, Immunoglobulin Subclass Deficiency","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cuvitru 20 % Injectable Solution","genericName":"Cuvitru 20 % Injectable Solution","companyName":"University of Edinburgh","companyId":"university-of-edinburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cuvitru is a human immunoglobulin (antibody) replacement therapy that provides passive immunity by supplying functional antibodies to patients with primary immunodeficiency. Used for Primary immunodeficiency disorders requiring immunoglobulin replacement, Secondary immunodeficiency in patients unable to produce adequate antibodies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}